In this study we have re-examined D-ribose treatment in four adenylosuccinate lyase (ADSL) deficient patients. Assessments consisted of biochemical markers and neurological outcome.
The 12-month trial of D-ribose failed to show any clinical benefit in ADSL deficient patient. Therefore, we could not confirm a positive effect of D-ribose as previously reported.